Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Mitogen-activated protein kinase 14 | ||
Ligand | BDBM50175761 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_328207 (CHEMBL863946) | ||
IC50 | 5.3±n/a nM | ||
Citation | Bao, J; Hunt, JA; Miao, S; Rupprecht, KM; Stelmach, JE; Liu, L; Ruzek, RD; Sinclair, PJ; Pivnichny, JV; Hop, CE; Kumar, S; Zaller, DM; Shoop, WL; O'neill, EA; O'keefe, SJ; Thompson, CM; Cubbon, RM; Wang, R; Zhang, WX; Thompson, JE; Doherty, JB p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones. Bioorg Med Chem Lett16:64-8 (2005) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
Mitogen-activated protein kinase 14 | |||
Name: | Mitogen-activated protein kinase 14 | ||
Synonyms: | CSAID-binding protein | CSBP | CSBP1 | CSBP2 | CSPB1 | Cytokine suppressive anti-inflammatory drug-binding protein | MAP kinase 14 | MAP kinase MXI2 | MAP kinase p38 alpha | MAPK 14 | MAPK14 | MAX-interacting protein 2 | MK14_HUMAN | MXI2 | Mitogen-activated protein kinase p38 alpha | SAPK2A | Stress-activated protein kinase 2a | p38 MAP kinase alpha/beta | ||
Type: | Serine/threonine-protein kinase | ||
Mol. Mass.: | 41286.76 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q16539 | ||
Residue: | 360 | ||
Sequence: |
| ||
BDBM50175761 | |||
n/a | |||
Name | BDBM50175761 | ||
Synonyms: | 7-(1-tert-butylpiperidin-4-yl)-5-(2-chloro-4-fluorophenyl)-1-(2,6-dichlorophenyl)-1,6-naphthyridin-2(1H)-one | CHEMBL199291 | ||
Type | Small organic molecule | ||
Emp. Form. | C29H27Cl3FN3O | ||
Mol. Mass. | 558.902 | ||
SMILES | CC(C)(C)N1CCC(CC1)c1cc2n(-c3c(Cl)cccc3Cl)c(=O)ccc2c(n1)-c1ccc(F)cc1Cl |(3.3,5.4,;1.97,4.62,;2.74,3.29,;1.2,5.95,;.64,3.85,;.63,2.31,;-.69,1.54,;-2.04,2.31,;-2.04,3.85,;-.7,4.62,;-3.37,1.53,;-4.7,2.3,;-6.03,1.52,;-7.36,2.29,;-7.36,3.83,;-8.69,4.59,;-10.02,3.82,;-8.7,6.13,;-7.36,6.9,;-6.02,6.13,;-6.02,4.59,;-4.69,3.82,;-8.7,1.52,;-10.04,2.29,;-8.7,-.02,;-7.36,-.8,;-6.03,-.02,;-4.7,-.79,;-3.36,-.02,;-4.7,-2.33,;-6.03,-3.1,;-6.03,-4.63,;-4.7,-5.41,;-4.7,-6.95,;-3.36,-4.63,;-3.37,-3.09,;-2.03,-2.32,)| | ||
Structure |